Cargando…
Identifying developability risks for clinical progression of antibodies using high-throughput in vitro and in silico approaches
With the growing significance of antibodies as a therapeutic class, identifying developability risks early during development is of paramount importance. Several high-throughput in vitro assays and in silico approaches have been proposed to de-risk antibodies during early stages of the discovery pro...
Autores principales: | Jain, Tushar, Boland, Todd, Vásquez, Maximiliano |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10114995/ https://www.ncbi.nlm.nih.gov/pubmed/37072706 http://dx.doi.org/10.1080/19420862.2023.2200540 |
Ejemplares similares
-
An alternative assay to hydrophobic interaction chromatography for high-throughput characterization of monoclonal antibodies
por: Estep, Patricia, et al.
Publicado: (2015) -
Deamidation and isomerization liability analysis of 131 clinical-stage antibodies
por: Lu, Xiaojun, et al.
Publicado: (2018) -
High throughput cross-interaction measures for human IgG1 antibodies correlate with clearance rates in mice
por: Kelly, Ryan L, et al.
Publicado: (2015) -
IspE Inhibitors Identified by a Combination of In Silico and In Vitro High-Throughput Screening
por: Tidten-Luksch, Naomi, et al.
Publicado: (2012) -
Broad epitope coverage of a human in vitro antibody library
por: Sivasubramanian, Arvind, et al.
Publicado: (2016)